Viking Therapeutics Stock Climbs On Q2 EPS Beat
Viking Therapeutics Stock Climbs On Q2 EPS Beat
Research and development expenses were $23.8 million for the quarter, compared to $13.9 million for the same period in 2023. Viking said the increase was primarily due to increased expenses related to manufacturing for the company's drug candidates, clinical studies, pre-clinical studies, salaries and benefits and stock-based compensation.Viking Therapeutics, Inc. (NASDAQ:VKTX) shares are trading higher after the company reported its second-quarter financial results Wednesday. Here's a look at the key figures from the report.
維京製藥股份有限公司（納斯達克：VKTX）股價在週三發佈第二季度業績後上漲。以下是報告的主要數字。
The Details: Viking Therapeutics reported quarterly losses of 20 cents per share which beat the analyst consensus estimate of losses of 27 cents by 25.93%.
詳情：維京製藥每股虧損20美分，超出了分析師虧損27美分的共識估計25.93%。
Viking reported a net loss of $22.3 million for the second quarter, compared to a net loss of $19.2 million in the corresponding period in 2023. The increase in net loss for the three months ended June 30, 2024, was primarily due to the increase in research and development expenses and general and administrative expenses, noted previously, partially offset by increased interest income, compared to the same period in 2023.
維京報告第二季度淨虧損2230萬美元，去年同期爲淨虧損1920萬美元，截至2024年6月30日的三個月的淨虧損增長主要是由於研發費用和一般管理費用的增加造成的，前述部分抵消了增加的利息收入。
Research and development expenses were $23.8 million for the quarter, compared to $13.9 million for the same period in 2023. Viking said the increase was primarily due to increased expenses related to manufacturing for the company's drug candidates, clinical studies, pre-clinical studies, salaries and benefits and stock-based compensation.
本季度研發費用爲2380萬美元，去年同期爲1390萬美元。維京表示，增加主要是由於增加的製造公司藥物候選人、臨床研究、前臨床研究、工資和福利以及股票補償等費用。
Read Also: What's Going On With Meta Stock?
閱讀也可以：Meta股票發生了什麼？
"The first half of 2024 was marked by strong momentum in the company's pipeline programs, as we reported successful outcomes from three different clinical trials, and began preparing for next steps with each program," stated Brian Lian, Ph.D., CEO of Viking.
維京製藥的CEO Brian Lian博士表示：“2024年上半年公司管線計劃的勢頭強勁，我們報告了三個不同臨床試驗的成功結果，併爲每個計劃開始準備下一步工作。”
"The Phase 2 VENTURE study of VK2735 in obesity demonstrated up to an approximately 15% reduction in body weight from baseline following 13 weeks of dosing, as well as promising safety and tolerability. Following receipt of written feedback from an FDA Type C meeting, we are advancing this compound into Phase 3 development. We are currently preparing for an end of Phase 2 meeting with the agency, which we expect to occur later this year," Lian added.
Lian博士補充說：“ VK2735（治療肥胖症）的2期VENTURE研究表明，在13周的給藥後，與基線相比，體重可減少約15％，並且具有良好的安全性和耐受性。在獲得FDA Type C會議的書面反饋後，我們正在推進該化合物進入3期開發。我們目前正在爲與監管機構的2期結束會議做準備，我們預計將於今年晚些時候進行。”
VKTX Price Action: According to Benzinga Pro, Viking Therapeutics shares are up 10.10% after-hours at $55.50 at the time of publication Wednesday.
根據Benzinga Pro的數據，發佈時間爲週三，維京製藥股份有限公司的股價在盤後上漲10.10％，爲55.50美元。
- What's Going On With Riot Platforms Stock?
- Riot Platforms股票出了什麼問題？
Image: Csaba Nagy from Pixabay
圖片：來自Pixabay的Csaba Nagy